# ACHIEVE LIFE SCIENCES, INC. (ACHV) — capital_raise/private_placement [completed]
Source: SEC API (secapi.ai) · situation sit_0364456a82090db6f954 · retrieved 2026-08-14T01:43:24.194Z

## Overview
Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence.

Achieve Life Sciences, Inc. closed a private placement of up to $354 million in total consideration, consisting of $180 million in upfront proceeds and up to $174 million from milestone-based warrants exercisable prior to and up to 20 trading days following FDA approval of cytisinicline. The company intends to use the proceeds to fund the ORCA-V2 Phase 3 trial, commercialization of cytisinicline, and working capital and general corporate purposes.

## Terms
- Deal value: $354.0M · Consideration: mixed

## Key dates
- Completed 2026-08-11

## Timeline
- 2026-08-11 · 8-K (0001193125-26-344571): 8-K - ACHIEVE LIFE SCIENCES, INC. — *Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence.* Achieve Life Sciences, Inc. closed a private placement of up to $354 million in total consideration, consisting of $180 million in upfront proceeds and up to $174 million from milestone-based warrants exercisable prior to and up to 20 trading days following FDA approval of cytisinicline. The company intends to use the proceeds to fund the ORCA-V2 Phase 3 trial, commercialization of cytisinicline, and working capital and general corporate purposes.
  https://www.sec.gov/Archives/edgar/data/949858/0001193125-26-344571.txt

## Citations
- 0001193125-26-344571 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526344571